Healing Joints. Restoring Lives.
Osteoarthritis is one of the most common and devastating chronic conditions in companion animals yet innovation in treatment has lagged behind the need.
An estimated 1 in 5 adult dogs and up to 80% of senior dogs suffer from osteoarthritis. These animals live with progressive pain, limited mobility, and a declining quality of life.
Current options like pain medications, anti-inflammatories, and surgery offer only temporary relief. None are designed to restore joint function.
It doesn’t have to be this way.
SEVA-101
A Breakthrough in Disease-Modifying Osteoarthritis Therapy
SEVA-101 is an off-the-shelf, intra-articular regenerative therapy developed to treat osteoarthritis in companion animals. Built on the same platform used for human health, SEVA-101 has shown robust cartilage regeneration in preclinical models delivering disease-modifying results that go beyond managing pain.
A Regenerative Solution for Companion Animals
True disease modification: Acts at the source of osteoarthritic degeneration, not just its symptoms.
Improved mobility and quality of life: Regenerates cartilage and slows disease progression.
Minimally invasive: Delivered as a convenient intra-articular injection.
Built for Scalability, Backed by Science
Using iPSC-derived cartilage, SEVA-101 offers consistent, high-quality exosomes rich in regenerative factors including proteins, lipids, and nucleic acids and optimized for veterinary application.
Multi-Pathway Impact
SEVA-101 targets pathways critical to:
Joint tissue repair
Inflammation resolution
Cartilage health and regeneration
This multi-modal, disease-modifying mechanism supports long-term joint health and function, offering a powerful new approach for managing OA in pets.
SEVA-101 contents are known to promote key pathways in Cartilage Regeneration, Extracellular Matrix Production, Reduced Inflammation, and Chondrogenic Differentiation suggesting a multi-modal MOA.
